Deepa Rangachari - Concepedia

Author

Deepa Rangachari

Harvard University

Also Known As

D. Rangachari, Deepa Rangachari, Luis Paz-Ares

Publications

540

Citations

H-Index

Concepts

All Affiliations

Harvard University Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute

About

Deepa Rangachari is an author at Harvard University specializing in oncology, medicine, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	262
2	Pathology	2	2	107
3	Cell Biology	1	1	34
4	Immunology	1	1	73
5	Surgical Oncology	1	1	155

Deepa Rangachari

Publications

471

Citations

H-Index

Page 1

	Year	Citations
Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy Kartik Sehgal, Ritu R. Gill, Page Widick, JAMA Network Open	2021	157
Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival George J. Arnaoutakis, Deepa Rangachari, Daniel A. Laheru, Journal of Gastrointestinal Surgery Surgical OncologyPancreatic CancerMedicinePancreatic SurgeryThoracic Surgery	2011	155
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors Rebecca Karp Leaf, Christopher Ferreri, Deepa Rangachari, American Journal of Hematology ImmunologyIcpi InitiationPathologyImmunotherapeuticsImmunotherapy	2019	73
Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature Camille R. Petri, Rushad Patell, Felipe Batalini, Respiratory Medicine Case Reports	2019	40
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors Xiuning Le, Neelam V. Desai, Adnan Majid, Lung Cancer MedicinePathologyEgfr InhibitorsBronchial NeoplasmPulmonary Blastoma	2015	34
EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Cells	2021	12

Page 1